A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy.

ABSTRACT:

Background

Oncolytic adenoviral virotherapy (OV) is a highly promising approach for the treatment of glioblastoma multiforme (GBM). In practice, however, the approach is limited by poor viral distribution and spread throughout the tumor mass.

Methods

To enhance viral delivery, replication, and spread, we used a US Food and Drug Administration-approved neural stem cell line (NSC), HB1.F3.CD, which is currently employed in human clinical trials. HB1.F3.CD cells were loaded with an oncolytic adenovirus, CRAd-Survivin-pk7, and mice bearing various human-derived GBMs were assessed with regard to NSC migration, viral replication, and therapeutic efficacy. Survival curves were evaluated with Kaplan-Meier methods. All statistical tests were two-sided.

Results

Antiglioma activ

SUBMITTER: Ahmed AU 

PROVIDER: S-EPMC3699440 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature